ab75898 を使用した論文を発表された方は、こちらまでお知らせください。データシートに掲載させていただきます。

ab75898 は 6 報の論文で使用されています。

  • Baratta MG  et al. An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. Proc Natl Acad Sci U S A 112:232-7 (2015). WB ; Human . PubMed: 25535366
  • Knoechel B  et al. An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. Nat Genet 46:364-70 (2014). WB ; Human . PubMed: 24584072
  • Liu P  et al. Release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein (snRNP) activates hexamethylene bisacetamide-inducible protein (HEXIM1) transcription. J Biol Chem 289:9918-25 (2014). WB ; Human . PubMed: 24515107
  • Hussong M  et al. The bromodomain protein BRD4 regulates the KEAP1/NRF2-dependent oxidative stress response. Cell Death Dis 5:e1195 (2014). Human . PubMed: 24763052
  • Puissant A  et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov 3:308-23 (2013). WB ; Human . PubMed: 23430699
  • Bartholomeeusen K  et al. Bromodomain and Extra-terminal (BET) Bromodomain Inhibition Activate Transcription via Transient Release of Positive Transcription Elongation Factor b (P-TEFb) from 7SK Small Nuclear Ribonucleoprotein. J Biol Chem 287:36609-16 (2012). WB . PubMed: 22952229

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"